The Food and Drug Administration Recommends Approval of Six Popular Peptides for Pharmacy Compounding
The Food and Drug Administration recommended the approval of six peptides for pharmacy compounding, rejecting only one substance for looser manufacturing restrictions. The panel, which included outside advisers and industry-connected experts, voted to recommend Epitalon, Semax, BPC-157, KPV, and TB-500 for various uses such as insomnia, cerebral ischemia, and wound healing. MOTS-C was also recommended for obesity treatment. While the administration announced the move toward approval, the decision faced scrutiny from career FDA scientists who argued that there is insufficient clinical evidence to confirm the safety and efficacy of several peptides, such as BPC-157. The panel was also criticized for being heavily influenced by industry-favored advisers. Health Secretary Robert F. Kennedy Jr. has advocated for the expedited reclassification of these peptides, arguing that the Biden administration's previous ban was overreaching. The approval of these peptides could pave the way for a multibillion-dollar industry, though the final decision rests with the FDA, which traditionally weighs the committee's advice heavily.